<p><b>TABLE OF INTERACTIONS WITH</b></p>

<p><b>BETA-BLOCKING AGENTS IN HEART FAILURE </b></p>

<p><b> At the present time, 4 beta blocking agents are indicated for “cardiac insufficiency”: carvedilol, bisoprolol, metoprolol, and nevibolol.</b></p>

<p><b>The drug interactions of these beta-blockers, when they are prescribed for cardiac insufficiency, can have more severe clinical consequences than those encountered when they are prescribed for other indications. Thus, certain combinations of drugs, currently seen in classic indications for beta-blockers, must be reconsidered in the light of this particular indication, often with a higher level of severity. </b></p>

<p><b> From the French ANSM drug interactions document of September 2016, pp. 42-43</b></p>

<table cellspacing="0" cellpadding="0" border="1">
<tbody>
<tr>
<td valign="top"><p><b>BETA-BLOCKING AGENTS IN HEART FAILURE</b></p>

<p><b>CLASS CODE: </b></p>

<p><b>C07AB-003</b></p></td>
<td valign="top"><p><b>AMIODARONE</b></p>

<p><b>RxNorm: 703 </b></p>

<p><b>ATC: C01BD01</b></p></td>
<td valign="top"><p>Disorders of autoregulation and of cardiac conduction with risk of excessive bradycardia.</p></td>
<td valign="top"><p><b>Precaution for use</b></p>

<p>Regular clinical monitoring and EKG</p>

</td>
</tr>

<tr>
<td valign="top"><p><b>BETA-BLOCKING AGENTS IN HEART FAILURE</b></p>

<p><b>CLASS CODE: </b></p>

<p><b>C07AB-003</b></p></td>
<td valign="top"><p><b>HALOGENATED HYDROCARBON ANESTHETICS</b></p>

<p><b>CLASS CODE: </b></p>

<p><b>N01AB0-001</b></p></td>
<td valign="top"><p>Reduction of the compensatory cardiovascular reactions by the beta-blocking agents. The beta-adrenergic inhibition can be elevated by the beta-stimulants during the surgery </p></td>
<td valign="top"><p><b>Precaution for use</b></p>

<p>As a general rule, do not stop the treatment with the beta blocking agent and, in any case, avoid stopping it abruptly. Inform the anesthesiologist of this treatment<b>.</b></p></td>
</tr>

<tr>
<td valign="top"><p><b>BETA-BLOCKING AGENTS IN HEART FAILURE</b></p>

<p><b>CLASS CODE: </b></p>

<p><b>C07AB-003</b></p></td>
<td valign="top"><p><b>CLASS I ANTIARRHYTHMICS (EXCEPT LIDOCAINE)</b></p>

<p><b>CLASS CODE: </b></p>

<p><b>C01B-003</b></p></td>
<td valign="top"><p>Negative inotropic effect with risk of acute decompensated heart failure</p></td>
<td valign="top"><p><b>CONTRAINDICATION</b></p></td>
</tr>

<tr>
<td valign="top"><p><b>BETA-BLOCKING AGENTS IN HEART FAILURE</b></p>

<p><b>CLASS CODE: </b></p>

<p><b>C07AB-003</b></p></td>
<td valign="top"><p><b>ACETYLCHOLINESTERASE INHIBITORS</b></p>

<p><b>CLASS CODE: </b></p>

<p><b>NO6DA-001</b></p></td>
<td valign="top"><p>Risk of excessive bradycardia (addition of the bradycardia inducing effects)</p></td>
<td valign="top"><p><b>Precaution for use</b></p>

<p>Regular clinical monitoring, especially at the beginning of the administration of the substances together </p></td>
</tr>

<tr>
<td valign="top"><p><b>BETA-BLOCKING AGENTS IN HEART FAILURE</b></p>

<p><b>CLASS CODE: </b></p>

<p><b>C07AB-003</b></p></td>
<td valign="top"><p><b>TRICYCLIC ANTIDEPRESSANTS</b></p>

<p><b>CLASS CODE: </b></p>

<p><b>N06AA-001</b></p></td>
<td valign="top"><p>Vasodilator effect and risk of hypotension, especially orthostatic (additive effect)</p></td>
<td valign="top"><p><b>Take into account</b></p></td>
</tr>

<tr>
<td valign="top"><p><b>BETA-BLOCKING AGENTS IN HEART FAILURE</b></p>

<p><b>CLASS CODE: </b></p>

<p><b>C07AB-003</b></p></td>
<td valign="top"><p><b>CENTRAL ANTIHYPERTENSIVES</b></p>

<p><b>CLASS CODE: </b></p>

<p><b>C02AC-001</b></p></td>
<td valign="top"><p>Central decrease of the sympathetic tone and vasodilator effect of the central antihypertensives, dangerous in cases of heart failure treated with a beta-blocking agent and vasodilator </p></td>
<td valign="top"><p><b>Not recommended</b></p></td>
</tr>

<tr>
<td valign="top"><p><b>BETA-BLOCKING AGENTS IN HEART FAILURE</b></p>

<p><b>CLASS CODE: </b></p>

<p><b>C07AB-003</b></p></td>
<td valign="top"><p><b>DIGOXIN </b></p>

<p><b>RxNorm: 3407</b></p>

<p><b>ATC: C01AA05</b></p></td>
<td valign="top"><p>Difficulties of autoregulation (bradycardia, sinus arrest) and of sinoatrial and atrioventricular conduction </p></td>
<td valign="top"><p><b>Take into account</b></p></td>
</tr>

<tr>
<td valign="top"><p><b>BETA-BLOCKING AGENTS IN HEART FAILURE</b></p>

<p><b>CLASS CODE: </b></p>

<p><b>C07AB-003</b></p></td>
<td valign="top"><p><b>DIHYDROPYRIDINES</b></p>

<p><b>CLASS CODE: </b></p>

<p><b>C08CA-002</b></p></td>
<td valign="top"><p>Hypotension, heart failure in patients with latent or uncontrolled cardiac insufficiency (negative iotropic effect of the dihydropyridines in vitro more or less marked and susceptible of adding to the negative inotropic effects of the beta-blocking agents). The presence of a beta-blocking treatment can furthermore minimize the sympathetic reflex reaction put into play in cases of excessive hemodynamic repercussion</p></td>
<td valign="top"><p><b>Take into account</b></p></td>
</tr>

<tr>
<td valign="top"><p><b>BETA-BLOCKING AGENTS IN HEART FAILURE</b></p>

<p><b>CLASS CODE: </b></p>

<p><b>C07AB-003</b></p></td>
<td valign="top"><p><b>DILTIAZEM</b></p>

<p><b>RxNorm: 3443</b></p>

<p><b>ATC: C08DB01</b></p></td>
<td valign="top"><p>Negative inotropic effect with risk of acute decompensated heart failure, disorders of autoregulation (bradycardia, sinus arrest), and disorders of sinoatrial and atrioventricular conduction</p></td>
<td valign="top"><p><b>CONTRAINDICATION</b></p></td>
</tr>

<tr>
<td valign="top"><p><b>BETA-BLOCKING AGENTS IN HEART FAILURE</b></p>

<p><b>CLASS CODE: </b></p>

<p><b>C07AB-003</b></p></td>
<td valign="top"><p><b>GLINIDES</b></p>

<p><b>CLASS CODE: </b></p>

<p><b>A10BX-001</b></p></td>
<td valign="top"><p>All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia</p></td>
<td valign="top"><p><b>Precaution for use</b></p>

<p>Inform the patient and, especially at the beginning of treatment, strengthen self-monitoring of blood glucose<b>.</b></p></td>
</tr>

<tr>
<td valign="top"><p><b>BETA-BLOCKING AGENTS IN HEART FAILURE</b></p>

<p><b>CLASS CODE: </b></p>

<p><b>C07AB-003</b></p></td>
<td valign="top"><p><b>INSULIN </b></p>

<p><b>RxNorm: 5856 </b></p>

<p><b>ATC:</b></p>

<p><b>A10AC01 A10AC02 A10AC03 A10AC04 A10AD01 A10AD02 A10AD03 A10AD04 A10AD05 A10AE01 A10AE02 A10AE03 A10AE04 A10AE05 A10AF01</b></p></td>
<td valign="top"><p>All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia</p></td>
<td valign="top"><p><b>Precaution for use</b></p>

<p>Inform the patient and, especially at the start of treatment, reinforce self-monitoring of blood glucose</p>

</td>
</tr>

<tr>
<td valign="top"><p><b>BETA-BLOCKING AGENTS IN HEART FAILURE</b></p>

<p><b>CLASS CODE: </b></p>

<p><b>C07AB-003</b></p></td>
<td valign="top"><p><b>LIDOCAINE</b></p>

<p><b>RxNorm: 6387</b></p>

<p><b>ATC:</b></p>

<p><b>C01BB01 C05AD01 D04AB01 N01BB02 R02AD02 S01HA07 S02DA01 N01BB52</b></p></td>
<td valign="top"><p>Negative inotropic effect with risk of acute decompensated heart failure</p></td>
<td valign="top"><p><b>Take into account</b></p></td>
</tr>

<tr>
<td valign="top"><p><b>BETA-BLOCKING AGENTS IN HEART FAILURE</b></p>

<p><b>CLASS CODE: </b></p>

<p><b>C07AB-003</b></p></td>
<td valign="top"><p><b>NEUROLEPTICS</b></p>

<p><b>CLASS CODE: </b></p>

<p><b>N05AA-003</b></p></td>
<td valign="top"><p>Vasodilator effect and risk of hypotension, especially orthostatic (additive effect)</p></td>
<td valign="top"><p><b>Take into account</b></p></td>
</tr>

<tr>
<td valign="top"><p><b>BETA-BLOCKING AGENTS IN HEART FAILURE</b></p>

<p><b>CLASS CODE: </b></p>

<p><b>C07AB-003</b></p></td>
<td valign="top"><p><b>SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES</b></p>

<p><b>CLASS CODE: C01-N05</b></p></td>
<td valign="top"><p>Increased risk of ventricular arrythmias, especially of torsades de pointes</p></td>
<td valign="top"><p><b>Precaution for use</b></p>

<p>Clinical monitoring and EKG.</p></td>
</tr>

<tr>
<td valign="top"><p><b>BETA-BLOCKING AGENTS IN HEART FAILURE</b></p>

<p><b>CLASS CODE: </b></p>

<p><b>C07AB-003</b></p></td>
<td valign="top"><p><b>BLOOD GLUCOSE LOWERING SULFONAMIDES</b></p>

<p><b>CLASS CODE: </b></p>

<p><b>A10BB</b></p></td>
<td valign="top"><p>All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia</p></td>
<td valign="top"><p><b>Precaution for use</b></p>

<p>Inform the patient and reinforce self-monitoring of blood glucose, especially at the beginning of treatment<b>. </b></p></td>
</tr>

<tr>
<td valign="top"><p><b>BETA-BLOCKING AGENTS IN HEART FAILURE</b></p>

<p><b>CLASS CODE: </b></p>

<p><b>C07AB-003</b></p></td>
<td valign="top"><p><b>VERAPAMIL</b></p>

<p><b>RxNorm: 11170 </b></p>

<p><b>ATC: C08DA01 </b></p></td>
<td valign="top"><p>Negative inotropic effect with risk of acute decompensated heart failure, disorders of autoregulation (bradycardia, sinus arrest) and disorders of sinoatrial and atrioventricular conduction </p></td>
<td valign="top"><p><b>CONTRAINDICATION</b></p></td>
</tr>

</tbody>
</table>

